Marshall Edwards, Inc. Announces Grants Under Nasdaq Rule 5635 SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - April 29, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer...

Marshall Edwards, Inc. Announces Resignation of Christopher Naughton From Board of Directors SYDNEY, AUSTRALIA--(Marketwire - February 8, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL) announced that Christopher Naughton had resigned as a member of the Board of Directors effective February 5,...

Analysis of Marshall Edwards, Inc.'s OVATURE Trial to Proceed Following Database Lock NEW CANAAN, CT--(Marketwire - January 21, 2010) - The Board of Directors of Marshall Edwards, Inc. today advised that analysis of tumor response data from the OVATURE trial will be performed in the...

New Data on Novogen Oncology Pipeline to Be Released SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - October 23, 2007) - New data on the Novogen oncology pipeline compound NV-128 will be presented on October 23 at the annual AACR/EORTC/NCI...

Yale Cancer Center Sponsors Study of Phenoxodiol for Prostate Cancer NEW HAVEN, CT--(Marketwire - October 22, 2007) - Yale researchers have begun recruiting 60 men for a clinical trial investigating an experimental new drug, oral phenoxodiol, as a potential first line...